Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Implementation of Flow Cytometric Monocyte Repartition Assay for Assessment of Chronic Myelomonocytic Leukaemia (CMML) in Bone Marrow

Sharon A Allen, MBBS, B.MDci(Path), Eugene Ng, BSc, Suzanne Edwards, GDipMStat, GDipMa, BN, Uwe H Hahn, MBBS, MD FRCPA, Tatjana Banovic, MBBS, MD PhD FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140932

Published: 2020

Journal Articles

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Andrew Charles Perkins, MBBS,PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Thomas Lehmann, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Andreas Reiter, MD, Vikas Gupta, MD FRCP, FRCPath, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Marielle Wondergem, MD, Robert Pack, PhD, Monika Wroclawska, MD, Celine Wilke, MD, Angela Zhang, PhD, Florian H. Heidel, MD

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-140408

Published: 2020

Journal Articles

Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

Francesco Passamonti, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Tarec Christoffer El-Galaly, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Brian Higgins, Ling-Yuh Huw, PhD, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD, John Mascarenhas, MD

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-136135

Published: 2020

Journal Articles

Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

John Mascarenhas, MD, Brian Higgins, Doreen Anders, Kate Burbury, MD, Tarec Christoffer El-Galaly, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Bruno Kovic, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, MD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD

Blood (2020) 136 (Supplement 1): 29–31.

https://doi.org/10.1182/blood-2020-135868

Published: 2020

Journal Articles

Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes

Naranie Shanmuganathan, FRACP,FRCPA,MBBS, Carol Wadham, PhD, Nur Hezrin Shahrin, PhD, Daniel Thomson, PhD BSc, Jinghua Feng, PhD, Verity A Saunders, Ming Lin, Rosalie Kenyon, Rob King, Paul Wang, PhD, David M Ross, MBBS, PhD FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Andreas W Schreiber, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Susan Branford, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136962

Published: 2020

Journal Articles

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Giuseppe Saglio, MD PhD, Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 1598.

https://doi.org/10.1182/blood.V130.Suppl_1.1598.1598

Published: 2017

Journal Articles

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Blood (2017) 130 (Supplement 1): 251.

https://doi.org/10.1182/blood.V130.Suppl_1.251.251

Published: 2017

Journal Articles

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Allison Scotch, MD MPH, Robyn M. Scherber, MD, Marlene Bruso, MS, Heidi Elizabeth Kosiorek, MS, Amylou C. Dueck, PhD, Holly Geyer, MD, Veena D. S. Fauble, MD, Alessandro M. Vannucchi, Ana Kerguelen Fuentes, Christen Lykkegaard Andersen, PhD, Elisabeth Ejerblad, MD, Gunnar Birgegard, MD PhD, Peter L. Johansson, MD PhD, Bjorn Andreasson, David M Ross, MBBS, PhD FRACP, FRCPA, Federico Sackman, MD PhD, Jean-Loup Demory, MD PhD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Jan J. Michiels, PhD, Deepti Radia, MD, Joanne Ewing, PhD BMBS, BSc, FRPATH,, Frances Wadelin, MD, Robert N. Lown, MBBS, MRCP, MD, Mary Frances McMullin, MB,Bch BAO, MD FRCPath, Wunna Swe, Jonathan O. Cullis, MD, Nigel Sargant, BSc, FRPATH, MRCP,, Paul Moreton, MD MRCP, FRCPath, Catherine Cargo, MB, FRCPath, Mallika Sekhar, MBBS, MD FRCPath, FRCP, Satareh Shekouhi, Ruben A Mesa, MD

Blood (2017) 130 (Supplement 1): 1641.

https://doi.org/10.1182/blood.V130.Suppl_1.1641.1641

Published: 2017

Journal Articles

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Markus Pfirrmann, Francois-Xavier Mahon, MD PhD, Joelle Guilhot, PhD, Johan Richter, MD PhD, Francis J. Giles, MD MB, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Giuseppe Saglio, MD PhD, Weiping Deng, Darshan Dalal, MPH, MD PhD, Susanne Saussele, MD

Blood (2017) 130 (Supplement 1): 1601.

https://doi.org/10.1182/blood.V130.Suppl_1.1601.1601

Published: 2017

Journal Articles

Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to TP53 Mutations in Therapy-Related Myeloid Neoplasms

Blood (2017) 130 (Supplement 1): 4231.

https://doi.org/10.1182/blood.V130.Suppl_1.4231.4231

Published: 2017

Journal Articles

Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS)

Deepak Singhal, MBBS, MD FRCPA, FRACP, Monika M Kutyna, MSc, Rakchha Chhetri, MBBS, Amilia Wee, BSc (Hons), Sophia Hague, Lakshmi Nath, MDDM,FRCPA, Shriram V Nath, MBBS, DM, FRCPA, Romi Sinha, MBBS, Nicholas Wickham, FRCPA,FRACP,FRCPath, Ian D Lewis, MBBS, PhD FRACP, FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, FRCPath, Luen Bik To, MBBS, FRACP, FRCPA, PhD, John Reynolds, PhD, Erica Wood, David John Roxby, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2017) 130 (Supplement 1): 2411.

https://doi.org/10.1182/blood.V130.Suppl_1.2411.2411

Published: 2017

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francois-Xavier Mahon, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Giuseppe Saglio, MD PhD

Blood (2017) 130 (Supplement 1): 2878.

https://doi.org/10.1182/blood.V130.Suppl_1.2878.2878

Published: 2017

Journal Articles

Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms

Christopher N Hahn, PhD, Amilia Wee, BSc (Hons), Milena Babic, BMPharBio (Hons), Jinghua Feng, PhD, Paul Wang, Monika M Kutyna, MSc, Sarah Moore, BSc (Hon), FFSc (RCPA), Anna L Brown, PhD, Richard D'Andrea, BSc,PhD, Deepak Singhal, MBBS, MD FRCPA, FRACP, Andreas Schreiber, PhD, Pratyush Giri, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS

Blood (2017) 130 (Supplement 1): 492.

https://doi.org/10.1182/blood.V130.Suppl_1.492.492

Published: 2017

Journal Articles

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Naranie Shanmuganathan, MBBS, Susan Branford, PhD, David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Agnes S. M. Yong, MDPhD, David M Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1621.

https://doi.org/10.1182/blood.V130.Suppl_1.1621.1621

Published: 2017

Journal Articles

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

David M Ross, MBBS, PhD FRACP, FRCPA, Ilaria S Pagani, PhD, Naranie Shanmuganathan, MBBS, John F Seymour, MBBS, PhD, Anthony K Mills, FRACP, FRCPA, MBBS, Robin J Filshie, PhDFRACP,FRCPA, Christopher K Arthur, MDFRACP,FRCPA,MBBS, Phuong Dang, Verity A Saunders, Jody Braley, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Deborah L White, PhD FFSc (RCPA), Andrew P Grigg, MBBS, MD FRACP, FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Susan Branford, PhD, Timothy P. Hughes, MD

Blood (2017) 130 (Supplement 1): 1597.

https://doi.org/10.1182/blood.V130.Suppl_1.1597.1597

Published: 2017

Journal Articles

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, MD, Maria Teresa Gómez Casares, MDPhD, Jesper Stentoft, MD PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Valentin García-Gutiérrez, MD, Norbert Gattermann, MD, Wieslaw Wiktor-Jedrzejczak, MD, Philipp D. Le Coutre, MD, Bruno Martino, MD, Susanne Saussele, MD, Francis J. Giles, MB, MD FRCPI, FRCPath, Jerald P. Radich, David M. Ross, MBBS, PhD FRACP, FRCPA, Hans D. Menssen, MD PhD, Weiping Deng, Patricia Brandt, Ari Gnanasakthy, MBA, MSc, Veronique Bedoucha, Giuseppe Saglio, MD

Blood (2016) 128 (22): 3066.

https://doi.org/10.1182/blood.V128.22.3066.3066

Published: 2016

Journal Articles

Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation

Amy Hughes, PhD, Jade Clarson, B.Sc, Deborah L White, PhD FFSc (RCPA), David M. Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Agnes S Yong, MD PhD

Blood (2016) 128 (22): 1122.

https://doi.org/10.1182/blood.V128.22.1122.1122

Published: 2016

Journal Articles

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

Justine E Marum, PhD, Paul PS Wang, PhD, Doris Stangl, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Martin C. Mueller, Christian T. Dietz, PhD, Ieuan Walker, MSc, BSc, MBBS, Nathalie Nataren, BSc, Zoe Donaldson, BSc, Wendy T Parker, PhD, David M. Ross, MBBS, PhD FRACP, FRCPA, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Andreas W Schreiber, PhD, Susan Branford, PhD FFSc (RCPA)

Blood (2016) 128 (22): 1219.

https://doi.org/10.1182/blood.V128.22.1219.1219

Published: 2016

Journal Articles

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Allison H Scotch, MD MPH, Robyn M. Scherber, MD MPH, Nan Zhang, MS, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Holly Geyer, MD, Veena Fauble, MD, Alessandro M. Vannucchi, MD PhD, Ana Kerguelen Fuentes, Christen Lykkegaard Andersen, MD PhD, Elisabeth Ejerblad, MD, Gunnar Birgegard, MD PhD, Peter L. Johansson, MD PhD, Bjorn Andreasson, David M. Ross, MBBS, PhD FRACP, FRCPA, Federico Sackmann, MD, Jean-Loup Demory, MD, Constantine S. Tam, Jan J. Michiels, PhD, Deepti Radia, MBBS, MRCPI, FRCPath MSc, MD, Mohan Mahalakshmi, MD, Daniel Jennings, Joanne C Ewing, PhD BMBS, BSc, FRPATH,, Frances Wadelin, MD, Robert N Lown, MBBS, MDRes), MRCP, FRCPath, Victoria Drew, John Hudson, Mary Frances McMullin, MD, Wunna Swe, Jonathan O. Cullis, MD MB, BS, MA, FRCP, FRCPath, Nigel Sargant, BSc, FRPATH, MRCP,, Paul Moreton, MD MRCP, MRCPath, Mari Frances Kilner, MBBS,MRCP,FRCPath, Catherine Cargo, MB, FRCPath, Mallika Sekhar, MBBS,MDFRCPath,FRCP, Satareh Shekouhi, Ruben A. Mesa, MD

Blood (2016) 128 (22): 5479.

https://doi.org/10.1182/blood.V128.22.5479.5479

Published: 2016

NARROW

Implementation of Flow Cytometric Monocyte Repartition Assay for Assessment of Chronic Myelomonocytic Leukaemia (CMML) in Bone Marrow

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Molecular Response Patterns in Hydroxyurea (HU)-Resistant or Intolerant Polycythemia Vera (PV) during Treatment with Idasanutlin: Results of an Open-Label, Single-Arm Phase 2 Study

Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study

Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to TP53 Mutations in Therapy-Related Myeloid Neoplasms

Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS)

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTfreedom Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: Interim Results from the MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only